Avanos Medical, Inc. (NYSE: AVNS) reported Q2 EPS of $0.21, $0.02 worse than the analyst estimate of $0.23. Revenue for the quarter came in at $186 million versus the consensus estimate of $180.56 million.

GUIDANCE:

Avanos Medical, Inc. sees FY2021 EPS of $1.10-$1.20, versus the consensus of $1.21.

For earnings history and earnings-related data on Avanos Medical, Inc. (AVNS) click here.